Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director, Investor Relations and Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer and Head, Research Sean Moran - Chief Financial Officer Craig Millian - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Maurice Raycroft - Jefferies Leland Gershell - Oppenheimer Jonathan Wolleben ...

Pioneering transformative medicines that target the endocannabinoid system NASDAQ: CRBP @corbuspharma www.corbuspharma.com TM Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 per share CRBP Nasdaq Global Market Emerging growth company [X] FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director, Investor Relations & Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer Craig Millian - Chief Commercial Officer. Conference Call Participants Brian Abrahams - RBC Liisa Bayko - JMP Securities Maury Raycroft - Jefferies Ted Tenthoff - Piper Jaffray George Zavoico - B. Riley FBR Operator Good mornin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period June 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (State ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements 2 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director of IR and Corporate Communications Yuval Cohen - CEO Barbara White - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Leland Gershell - Oppenheimer and Company George Zavoico - B. Riley FBR Operator Greetings, and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period March 31, 2019. or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ . Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-434803 ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements 2 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible ...